Stanford University
Showing 1,401-1,410 of 2,333 Results
-
Yair Blumenfeld, MD
Professor of Obstetrics and Gynecology (Maternal Fetal Medicine)
Current Research and Scholarly Interestsprenatal diagnosis, genetics, clinical obstetrics
-
Mark S. Blumenkranz, MD, MMS
H. J. Smead Professor of Ophthalmology, Emeritus
Current Research and Scholarly InterestsClinical Interest and Research
My primary areas of interest are in the diagnosis, medical and surgical treatment of vitreal retinal diseases. These principally include age-related macular degeneration and other diseases of the macula, and tractional syndromes, diabetic retinopathy, and complex forms of retinal detachment. I have been interested in the development of novel technology to diagnose and treat these diseases, including new forms of imaging, laser delivery systems, other microsurgical tools, and new drugs and drug delivery systems that inhibit new blood vessel growth, scarring and intraocular inflammation. I have been actively involved in translational research in the laboratory as well as technology transfer associated with that research for a variety of new therapies that have received FDA clearance and been introduced into clinical practice over the past 30 years.
Administrative and Community Service
I have served on the Board of Directors of a variety of voluntary education and service organizations, including the Corporation of Brown University, multiple scientific advisory boards and various philanthropic and research organizations. -
Paul D. Blumenthal, MD, MPH
Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus
Current Research and Scholarly InterestsImproving Access to Family Planning Services in Low Resource Settings:
Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs. -
Mr Mark Blumling
Lecturer, Law Teaching
BioMark Blumling is an Executive Advisor at New Mountain Capital. Mark is the former CEO and Founder of Headlands Research, a KKR-backed clinical research site company. Mark was previously CEO and Co-Founder of Genos, a big data healthcare technology company (acquired in 2017) and CEO of Relevare Pharmaceuticals, a pharmaceutical company based in San Francisco and Melbourne, Australia. Prior to joining Relevare, Mark was Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired in 2015) as well as a Director at Burrill & Company, where he worked in private equity, venture capital, and investment banking. Mark began his career in the Office of Science & Technology (R&D) at SmithKline Beecham, where he was involved in the creation and development of new business ventures, and at Orchid Biosciences (NASDAQ: ORCH).
Mark received a JD from Stanford Law School, an MSc (Economics) from the London School of Economics, and a BA in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.
